Lifecore Biomedical Inc (LFCR) Q1 2025 Earnings Call Transcript Highlights: Navigating ...

GuruFocus News
4 min read

In This Article:

  • Revenue: $24.7 million for Q1 fiscal 2025, up from $24.5 million in Q1 fiscal 2024.

  • Gross Profit: $5.4 million, compared to $2.7 million in the prior year period.

  • Selling, General and Administrative Expense: $14.8 million, up from $9.2 million in the prior year period.

  • Interest Expense: $5.4 million, increased from $3.9 million in the prior year period.

  • Net Loss: $16.2 million or $0.53 per diluted share, compared to a net loss of $10.8 million or $0.35 per diluted share in the prior year period.

  • Adjusted EBITDA: Negative $1.8 million, consistent with negative $2 million in the prior year period.

  • PIPE Offering: Successfully closed a $24.3 million PIPE offering.

Release Date: October 04, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • Lifecore Biomedical Inc (NASDAQ:LFCR) successfully raised $24.3 million through a PIPE offering, indicating strong shareholder confidence.

  • The company regained compliance with NASDAQ listing requirements, ensuring continued trading on the exchange.

  • Lifecore signed agreements with four new customers, including a significant partnership with Lindy Biosciences, enhancing its business development pipeline.

  • The installation and qualification of a high-speed multipurpose isolator filler doubled the company's capacity, potentially increasing revenue-generating capacity to $300 million annually.

  • The company is expanding its sales force and increasing participation in industry conferences, which could drive future business growth.

Negative Points

  • Lifecore Biomedical Inc (NASDAQ:LFCR) reported a net loss of $16.2 million for the quarter, an increase from the $10.8 million loss in the same period last year.

  • Interest expenses rose to $5.4 million from $3.9 million, primarily due to debt-related costs.

  • The company experienced a $1.3 million decrease in CDMO revenues as a result of customers working down inventory levels.

  • Selling, general, and administrative expenses increased significantly by $5.6 million, driven by higher professional fees and stock-based compensation.

  • Cash flow from operations was negative, and the company expects to burn cash in the first half of the fiscal year, raising concerns about liquidity.

Q & A Highlights

Q: Can you provide more details on the Lindy Biosciences opportunity and the potential to expand into their partner base? Also, could you give some color on the other new wins? A: We are excited about the Lindy opportunity, which highlights our technical capabilities. We were chosen for our technical strength, not price. The deal allows us to scale Lindy's technology to commercial scale and partner with their licensees for manufacturing. The other three wins are early-stage, with two in specialty pharma and one with a large multinational pharmaceutical company. - Paul Josephs, CEO

Recommended Stories